文献类型：期刊文献

英文题名：Meta-analysis on the safety and efficacy of Erdafitinib in treating FGFR1-4 mutated solid tumors

作者：Huang, Jiyu[1];Wang, Zihan[1];Zhao, Fei[1];Aisa, Adilai[1];Tian, Shengkai[1];Chen, Siyuan[2];Peng, Lianyi[1];Yang, Xiaolu[1];He, Jianxin[3,4];Yang, Yue[1]

第一作者：Huang, Jiyu

通信作者：Yang, Y[1]

机构：[1]Northwest Univ Nationalities, Med Coll, Lanzhou, Peoples R China;[2]China Med Univ, Shenyang, Liaoning, Peoples R China;[3]Gansu Univ Chinese Med, Lanzhou, Gansu, Peoples R China;[4]Gansu Univ Chinese Med, Key Lab Dunhuang Med & Transformat, Lanzhou, Gansu, Peoples R China

第一机构：Northwest Univ Nationalities, Med Coll, Lanzhou, Peoples R China

通信机构：[1]corresponding author), Northwest Univ Nationalities, Med Coll, Lanzhou, Peoples R China.

年份：2025

卷号：15

外文期刊名：FRONTIERS IN ONCOLOGY

收录：;Scopus(收录号：2-s2.0-105013879939);WOS:【SCI-EXPANDED(收录号:WOS:001555999800001)】；

基金：The author(s) declare financial support was received for the research and/or publication of this article. National Natural Science Foundation of China(8150377), Industry Support Plan Project of Gansu Provincial Department of Education(2022CYZC-54), Open Fund of Key Laboratory of Dunhuang Medicine, Ministry of Education(DHYX18-10), Youth Doctoral Fund of Universities in Gansu Province(2022QB-027), Talent Introduction Research Project of Northwest University for Nationalities (xbmuyjrc202235)

语种：英文

外文关键词：erdafitinib; urothelial carcinoma; FGFR1-4; tumors; meta-analysis

摘要：Objective: This article aims to analyze the safety and efficacy of Erdafitinib in the treatment of patients with advanced solid tumors harboring FGFR1-4 mutations. Methods: Search for relevant articles in databases such as PubMed, Embase, The Cochrane Library, Web of Science, and CNKI, covering the period from their establishment to October 25, 2024. Summarize the adverse drug reaction (AE) data, overall survival (OS), median progression-free survival (PFS), objective response rate (ORR), and other relevant data for patients with advanced solid tumors treated with Erdafitinib for FGFR1-4 mutations. Conduct a meta-analysis on the corresponding summarized data using the software Stata 18.0. Results: Through our search, we identified a total of 10 articles involving 1019 patients. In urothelial carcinoma, the most prevalent adverse reactions are hyperphosphatemia (78.5%), diarrhea (56.5%), and stomatitis (51.1%). The most frequently reported adverse reactions in other solid tumors are hyperphosphatemia (66.5%), dry mouth (48.5%), and diarrhea (44.9%). Patients with urothelial carcinoma treated with Erdafitinib exhibit higher median progression-free survival (PFS) and objective response rate (ORR) compared to those treated with other solid tumor therapies. Conclusion: Current evidence indicates that Erdafitinib exhibits certain therapeutic efficacy in the treatment of advanced solid tumors harboring FGFR1-4 mutations, with the most pronounced therapeutic effect observed in urothelial carcinoma. The efficacy of Erdafitinib in treating other solid tumors requires further confirmation through larger-scale studies involving a broader range of FGFR1-4 mutant tumors.